Navigation Links
GenVec Reports Second Quarter 2009 Financial Results
Date:8/6/2009

GAITHERSBURG, Md., Aug. 6 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) today announced its financial results for the second quarter ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

GenVec reported a net loss of $4.8 million ($0.05 per share) for the three months ended June 30, 2009 compared to a net loss of $6.6 million ($0.08 per share) in the comparable quarter of 2008. For the six months ended June 30, 2009, GenVec's net loss was $10.5 million ($0.12 per share), compared to a net loss of $12.8 million ($0.17 per share) for the six months ended June 30, 2008.

Revenues for the three-month and six-month periods ended June 30, 2009 were $3.8 million and $7.6 million, respectively, compared to revenues of $3.9 million and $7.6 million in the comparable prior year periods. For the three-month and six-month periods ended June 30, 2009 we experienced decreases in revenues associated with our FMD and malaria programs, partially offset by increased revenue associated with our HIV program, as compared to the comparable prior year periods. Lower revenues under both the FMD and malaria programs in each period are due mainly to the scope of work performed in the current periods as compared to the prior year. Also contributing to the lower revenue under the malaria program for the six-month period is the limited work conducted prior to the signing of the 2009 contract at the end of March 2009. The increase in revenue associated with our HIV program in each period is due mainly to increased research and process development efforts as compared to the comparable prior year periods.

Operating expenses were $8.6 million and $17.8 million for the three-month and six-month periods ended June 30, 2009, respectively, representing decreases of 20 percent and 14 percent as compared to $10.6 million and $20.8 million in the comparable prior year periods. The decrease in both periods is primarily due to lower personnel costs, reduced patient, site, lab, data management, monitoring and materials costs related to our TNFerade(TM) program, reduced materials costs related to our funded programs, and reduced general lab materials and supplies. Also contributing to the decrease are lower professional, facility, and recruiting costs. These decreases are partially offset in both periods by increases related to the manufacturing costs of TNFerade arising from the letter agreement and subsequent termination of our Cobra contract and increases related to manufacturing costs related to our FMD program as compared to the prior year periods.

GenVec ended the second quarter of 2009 with $12.6 million in cash and investments.

"Based on existing contracts and collaborations, we anticipate revenues for 2009 will be between $15.0 million and $18.0 million. We project our cash burn to be between $8.0 million and $11.0 million for the 12 months ending June 30, 2010," commented Douglas J. Swirsky, GenVec's Senior Vice President and Chief Financial Officer. "In spite of the difficult economic times, GenVec continues to make strides in its therapeutic and vaccine programs. We look forward to sharing additional data from our pivotal trial in locally-advanced pancreatic cancer early next year."

Second Quarter and Recent Highlights

TNFerade for Cancer

  • As of July 31, 2009, 262 patients have been enrolled in the GenVec's pivotal PACT trial.

  • GenVec presented data on its PACT trial at the annual meeting of the American Society for Clinical Oncology. The poster, entitled "Multi-Center Randomized Controlled Phase III Clinical Trial using TNFerade(TM) with Chemoradiation in Patients with Locally Advanced Pancreatic Cancer: Interim Analysis of Overall Survival," reported on results of an interim analysis from the PACT trial.

  • In June 2009, GenVec terminated its manufacturing agreement and its associated services schedule with Cobra BioManufacturing.

Vaccine Programs

  • GenVec expanded an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract is valued at approximately $2 million over two years.

  • GenVec received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's malaria vaccine program. This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development.

Other Developments

  • GenVec strengthened its cash position by raising $6.0 million from a single institutional investor. Proceeds of this transaction, net of offering costs, totaled $5.5 million.

Conference Call Information

GenVec will hold a conference call at 10:00 a.m. EDT on Friday, August 7, 2009 to discuss the Company's second quarter results. To listen to the live conference call, please dial 888-679-8033 (U.S. or Canada) or 617-213-4846 (international) and use access code 57544597. Participants may pre-register for the call anytime at: https://www.theconferencingservice.com/prereg/key.process?key=PNU6FNDG6. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 1:00 p.m. on August 7, 2009 through August 14, 2009. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 93256887.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to certain of our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

(Tables to Follow)

                                 GenVec, Inc.
                      Condensed Statements of Operations
                     (in thousands, except per share data)

                                   Three Months Ended  Six Months Ended
                                       June 30,             June 30,
                                      2009   2008       2009     2008
                                      ----   ----       ----     ----
                                      (Unaudited)         (Unaudited)
                                      -----------         -----------

    Revenue                         $3,781   $3,863    $7,576    $7,592

    Operating expenses:
       Research and development      7,096    8,356    14,385    16,049
       General and administrative    1,453    2,289     3,383     4,729
                                     -----    -----     -----     -----
          Total operating expenses   8,549   10,645    17,768    20,778
                                     -----   ------    ------    ------
    Loss from operations            (4,768)  (6,782)  (10,192)  (13,186)
       Interest income                   8      156        35       417
       Interest expense, net           (52)      73       (65)      (48)
       Other                             3        3      (268)        7
                                      ----     ----      ----      ----
    Net loss                       $(4,809) $(6,550) $(10,490) $(12,810)
                                   =======  =======  ========  ========

    Basic and diluted loss per
     share                          $(0.05)  $(0.08)   $(0.12)   $(0.17)
                                    ======   ======    ======    ======

    Shares used in computing basic
     and diluted net loss per share 92,053   78,707    90,356    77,073
                                    ======   ======    ======    ======



                      GenVec, Inc.
              Selected Balance Sheet Information
                     (in thousands)

                                               June 30, December 31,
                                                   2009         2008
                                                   ----         ----
                                            (Unaudited)

    Cash and investments                        $12,628      $17,357
    Working capital                               8,260       11,728
    Total assets                                 16,014       22,767
    Stockholders' equity                          9,192       13,091


'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Expands Contract Supporting Malaria Vaccine Program
2. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. OncoGenex Reports Second Quarter 2009 Financial Results
6. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
7. PDI Reports 2009 Second Quarter Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. NxStage Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):